title: [Combined external radiotherapy and 125I-particle implantation for treatment of head and neck cancers].
abstract: OBJECTIVE
  To evaluate the relative incidence of local control and toxicity in patients with head and neck cancers who underwent external beam radiotherapy (EBRT) plus (125)I seeds implantation.
  
  
  METHODS
  Ten patients diagnosed as head and neck cancers at the department of oral and maxillofacial surgery of Peking University School of Stomatology during the period of February 2008 to July 2010 were collected. The histologic types included squamous cell carcinoma in 8 patients, poorly differentiated adenocarcinoma of salivary gland in 2 patients. All patients could not receive surgical treatment due to poor medical status or unresectable advanced-stage tumors and underwent EBRT plus (125)I seeds implantation. Eight patients with squamous cell carcinoma had conventional fractionated EBRT with a total dose of 50 Gy; two patients with poorly differentiated adenocarcinoma had conventional fractionated EBRT with a total dose of 70 Gy. They all then had (125)I seeds implantation with matched peripheral dose of 60 Gy (TNM stage I-II) or 80 Gy (TNM stage III-IV ). The apparent activity per seed ranged from 25.9 to 29.6 MBq. follow-up of the patients was done to analyze acute and late toxicity, local control, and survival.
  
  
  RESULTS
  After a median follow-up of 12 months (range 2-28 months), soft tissue necrosis was seen in one patient, dysphagia and hemorrhage in another. No other serious side effects were observed. All the tumor mass of 10 cases disappeared within 6 months, regional metastases was observed in one patient, and distant metastases was observed in another. Seven of 10 patients survived till the date of investigation.
  
  
  CONCLUSIONS
  External beam radiotherapy plus (125)I seeds implantation is a safe and effective therapy regimen for patients with unrectable head and neck cancers.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Peking University School, Beijing 100081, China.
authors.forename: Shu ming
authors.initials: Sm
authors.lastname: Liu
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.forename: Lei
authors.initials: L
authors.lastname: Zheng
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.forename: Ming wei
authors.initials: Mw
authors.lastname: Huang
authors.forename: Jing li
authors.initials: Jl
authors.lastname: Zhu
authors.forename: Zu yan
authors.initials: Zy
authors.lastname: Zhang
authors.forename: Jian guo
authors.initials: Jg
authors.lastname: Zhang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy / Q000379:methods
chemical_list: D007457:Iodine Radioisotopes